CCL18 and systemic sclerosis: Given that CCL18 is associated with the progression and mortality in both SSc and IPF [12,14], the association of M2 macrophage phenotype with stat3 signaling in patients suffering from various types of pulmonary fibrosis including IPF may provide a molecular mechanism for CCL18 in fibrotic lung diseases [31].